Drug repurposing holds great promise to meet many of the unmet needs that still afflict patients across Europe. Repurposing, the process whereby existing licensed medicines are developed as treatments for diseases for which they are not currently approved, applies across all disease areas, from rare diseases to cancer to the COVID-19 pandemic.
EAT
EATRIS
Other · Netherlands · EU Transparency Register 125048092671-13
4
positions filed
in the 665 files tracked
4
legislative files
of 665 tracked
2
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 665 consultation files tracked so far (57,774 submissions, mostly 2021–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 171 other organisations on this site, they rank #55 by legislative files engaged, a count of participation, not a measure of influence.
0.4
declared lobbying FTE
self-declared
< €10K
declared costs / yr (floor)
0
EP accreditations
as declared to the register
2024
in the register since
Declares membership of
- EATRIS established partnerships with other research infrastructures and e-infrastructure providers to ensure that its…
- EATRIS is an observer of the EOSC Association, an active contributor to the EOSC development and is working to make i…
- EATRIS is a member of the Personalised Medicine Coalition (PMC).
- EATRIS is a partner of the EU Health Coalition.
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026).
- Register category
- Other organisations
- Registered as
- European Research Infrastructure for Translational Medicine (EATRIS)
- Head office
- Amsterdam, Netherlands
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track EATRIS in PolicySpeak: request access →
Work at EATRIS? so we know who speaks for it.
Their record over time
EATRIS filed 4 positions between 8 Nov 2023 and 19 Aug 2026, across 4 of the 665 legislative files tracked here, attaching a full position paper 2 times.
2023 · 1 filed2025 · 2 filed2026 · 1 filed
What they argued
EATRIS ERIC, the European Research Infrastructure for Translational Medicine, welcomes the European Commissions initiative to develop a European Biotech Act. For the Act to succeed in boosting EU competitiveness and resilience in the healthcare domain, it must directly tackle persistent systemic barriers across the innovation pipeline, 1.
EATRIS ERIC, the European Research Infrastructure for Translational Medicine, welcomes the Commissions effort to develop a forward-looking Strategy for Research and Technology Infrastructures (RITI), and fully supports the recognition of their strategic role in enhancing European competitiveness, scientific excellence, and health resilience.
Overall we agree broadly with the issues identified; these are the cogent challenges facing the EITs. We recommend (focused on life sciences but generally applicable): 1. make EITs less inward-looking: by making the EIT eco-system a visible and accessible value chain mandated to support all-comers with promising technologies. If this was already the case, it was not adequately visible 2.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put EATRIS next to another organization. Same files, same register facts, side by side. Compare →
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers, not evidence of coordination, and we do not suggest any.
Showing 5 of 91.
Is this your organization?
Everything on this page comes from EATRIS’s own submissions to the European Commission. We have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.